Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

BioCryst Pharmaceuticals Inc (NASDAQ:BCRX)

5.24
Delayed Data
As of Sep 22
 -0.03 / -0.57%
Today’s Change
3.75
Today|||52-Week Range
9.25
-17.22%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$421.6M

Company Description

BioCryst Pharmaceuticals, Inc. engages in the research, development, and commercialization of biopharmaceutical products. Its portfolio includes Rapivab, Kallikrein inhibitors, and BCX4430. These drugs intend to treat influenza and hereditary angioedema. The company was founded in 1986 and is headquartered in Durham, NC.

Contact Information

BioCryst Pharmaceuticals, Inc.
4505 Emperor Boulevard
Durham North Carolina 27703-8457
P:(919) 859-1302
Investor Relations:
(919) 859-7910

Employees

Shareholders

Other institutional59.62%
Individual stakeholders27.06%
Mutual fund holders27.01%

Top Executives

Jon P. StonehousePresident, Chief Executive Officer & Director
Robert BennettVice President-Investor Relations & Operations
Thomas R. StaabCFO, Treasurer, Principal Accounting Officer & SVP
William P. SheridanChief Medical Officer & Senior Vice President
Lynne M. PowellChief Commercial Officer & Senior Vice President